Clinical Trials · NCT03746041
A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- University of Rochester
- Enrollment
- 20
- Start date
- Feb 2019
- Locations
- 1 site, United States
- Primary endpoint
- Proportion of patients who experience a therapy-limiting Toxicity (TLT)